Date: 17 December 2014

Description: The NPCB would like to alert healthcare professionals that cases of serious skin reactions (Stevens Johnson Syndrome and acute generalised exanthematous pustulosis) have been reported with the use of Reminyl^®. Patients must be counselled on the signs of serious skin reactions, and Reminyl^® treatment should be discontinued at the first appearance of skin rash. For further details, please refer to the Direct Healthcare Professional Communication (DHPC) issued by Janssen, a division of Johnson & Johnson Sdn. Bhd., in agreement with NPCB.